Drug Profile
Research programme: cyclo-oxygenase 2 inhibitors - Beijing Orbiepharmacy Technology
Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator Beijing Orbiepharmacy Technology
- Class Imidazoles
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Inflammation in China (Parenteral, Injection)
- 28 Feb 2018 No recent reports of development identified for preclinical development in Inflammation in China (PO)